Free tool
Stocks near their 52-week high
We cover 62 companies trading within 5% of their own 52-week high. The median market value in the group is $34.89B. Across the group, the median move over the past trading day is +0.11%. 100% of the 62 with a 200-day average trade above it. Price change over the past year runs from +21.3% to +165.2% across the middle 80 percent of the group, with a median of +44.3%.
Other lists in this group
Table
62 of 3,992 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% | Oct 29, 2026 |
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% | Oct 13, 2026 |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% | Oct 13, 2026 |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% | Oct 29, 2026 |
| ABBV | AbbVie Inc. | $469.68B | Mega cap | +29.36% | Oct 29, 2026 |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% | Oct 29, 2026 |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% | Nov 3, 2026 |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% | Nov 3, 2026 |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% | Oct 21, 2026 |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% | Oct 21, 2026 |
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% | Oct 29, 2026 |
| PFE | Pfizer Inc. | $161.30B | Large cap | +18.72% | Nov 3, 2026 |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% | Nov 3, 2026 |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% | Nov 2, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% | Nov 2, 2026 |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% | Oct 29, 2026 |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | +39.36% | Oct 28, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% | Nov 5, 2026 |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +22.68% | Oct 29, 2026 |
| 4502.T | Takeda Pharmaceutical Company Limited | $58.08B | Large cap | +36.03% | Oct 29, 2026 |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% | Nov 5, 2026 |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% | Nov 5, 2026 |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% | Nov 4, 2026 |
| TEVA | Teva Pharmaceutical Industries Limited | $44.19B | Large cap | +110.08% | Nov 4, 2026 |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% | Nov 3, 2026 |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% | Nov 5, 2026 |
| WAT | Waters Corporation | $40.67B | Large cap | +40.57% | Oct 30, 2026 |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.39B | Large cap | +57.62% | Oct 29, 2026 |
| RPRX | Royalty Pharma plc | $35.71B | Large cap | +74.00% | Nov 4, 2026 |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% | Oct 29, 2026 |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% | Oct 29, 2026 |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +16.47% | Oct 29, 2026 |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% | Oct 29, 2026 |
| BIIB | Biogen Inc. | $32.66B | Large cap | +62.12% | Oct 29, 2026 |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% | Oct 29, 2026 |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% | Nov 3, 2026 |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% | Oct 20, 2026 |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% | Nov 9, 2026 |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% | Oct 27, 2026 |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% | Oct 28, 2026 |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +50.70% | Oct 27, 2026 |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% | Nov 5, 2026 |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% | Nov 5, 2026 |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% | Oct 27, 2026 |
| SOLV | Solventum Corporation | $15.58B | Large cap | +25.57% | Nov 5, 2026 |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.44B | Large cap | +11.27% | Nov 24, 2026 |
| 7733.T | Olympus Corporation | $14.46B | Large cap | +27.06% | Nov 10, 2026 |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% | Nov 4, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% | Oct 27, 2026 |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% | Oct 26, 2026 |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% | Oct 28, 2026 |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% | Nov 10, 2026 |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% | Nov 2, 2026 |
| TECH | Bio-Techne Corporation | $11.35B | Large cap | +29.33% | Nov 9, 2026 |
| PRAX | Praxis Precision Medicines, Inc. | $10.54B | Large cap | +704.28% | Nov 9, 2026 |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% | Nov 3, 2026 |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% | Oct 29, 2026 |
| HSIC | Henry Schein, Inc. | $10.30B | Large cap | +31.02% | Nov 3, 2026 |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% | Nov 3, 2026 |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% | Nov 9, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.